Why Device Authority’s automation is a game-changer

Tern plc

The digital security landscape is undergoing a seismic shift. With TLS certificate lifespans slashed from 398 to just 47 days, organisations face an urgent need to adapt. This article explores how Device Authority’s automation solutions are poised to transform certificate management, ensuring security and compliance in an increasingly complex environment.

The recent policy change by major tech players, reducing TLS certificate validity to a mere 47 days, marks a pivotal moment in cybersecurity. While the move aims to enhance security by limiting the window for potential breaches, it also introduces significant operational challenges. Organisations must now renew certificates nearly eight times more frequently, a task that is daunting, especially for those relying on manual processes.

Manual certificate management in today’s intricate IT and IoT ecosystems is not only inefficient but also unsustainable. The sheer volume of devices requiring regular certificate updates makes manual processes prone to errors, leading to potential outages and security breaches. Automation emerges as the indispensable solution, streamlining certificate provisioning, rotation, and revocation, thereby ensuring continuity and compliance with evolving security policies.

In the realm of IoT, the stakes are even higher. Devices often operate under constraints such as limited connectivity and resources, making traditional PKI management approaches inadequate. Device Authority recognises that IoT security demands more than just scaling existing PKI solutions; it requires tailored automation that considers the entire device lifecycle—from manufacturing and onboarding to operation and decommissioning.

Device Authority’s PKI automation solution addresses these challenges head-on. It offers policy-driven certificate management aligned with device identity, enabling scalable and secure onboarding through zero-touch provisioning. The solution automates renewal and revocation processes, eliminating the need for manual intervention and reducing the risk of human error. Moreover, it ensures auditability and compliance with stringent industry and regulatory standards.

As organisations navigate this new landscape, embracing automation becomes not just a strategic advantage but a necessity. Device Authority’s solutions provide the agility and resilience required to manage the accelerated certificate lifecycle effectively. By automating critical security processes, organisations can mitigate risks, maintain compliance, and focus on innovation and growth.

Device Authority is a leading provider of identity and access management solutions for the Internet of Things (IoT). Their flagship product, KeyScaler, delivers automated PKI and device identity lifecycle management, enabling secure onboarding, authentication, and data encryption for connected devices across various industries.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Search